학술논문
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Document Type
Article
Author
Isenberg, D.; Furie, R.; Jones, N.S.; Galanter, J.; Lee, C.; McGregor, A.; Toth, B.; Rae, J.; Hwang, O.; Desai, R.; Ramamoorthi, N.; Hackney, J.A.; Chinn, L.W.; Townsend, M.J.; Morimoto, A.M.; Tuckwell, K.; Guibord, P.; Lokku, A.; Miranda, P.; de Souza, V.A.; Jaller-Raad, J.J.; Maura Fernandes, A.; Garcia Salinas, R.
Source
In: Arthritis and Rheumatology . (Arthritis and Rheumatology, October 2021, 73(10):1835-1846)
Subject
Language
English
ISSN
23265205
23265191
23265191